Literature DB >> 6482488

Early and late prognosis after reoperation for prosthetic valve replacement.

X Bosch, J L Pomar, L C Pelletier.   

Abstract

From 1969 to 1983, 89 patients underwent replacement of a prosthetic heart valve, an average of 66 months after initial implantation, because of primary failure of the prosthesis in 39 patients (44%), endocarditis in 16 (18%), systemic valve-related complications in 16 (18%), and periprosthetic leaks in 13 (15%). In the remaining five patients (5%), a prosthesis was removed concomitantly with the replacement of another native heart valve. A mechanical valve was replaced in 64 cases (72%) and a bioprosthesis in 25 (28%). Forty-six of the prostheses (52%) were in the mitral position, 37 (42%) were in the aortic position, and six patients (6%) underwent replacement of two prostheses. Preoperatively, four patients were in Functional Class I, 21 in Class II, 37 in Class III, and 27 in Class IV. There were 19 early deaths (21.3%). Early mortality was significantly higher with aortic (35.1%) than with mitral prosthetic valve replacement (8.7%, p less than 0.01). Preoperative diagnosis had a significant correlation with mortality, which was higher with infective endocarditis (62.5%) than with all other indications for operation (12.3%, p less than 0.001). No correlation was found with the preoperative clinical class of the patients. During the time period of this study, there was a marked decline in the mortality rate, which decreased from 29.2% prior to 1979 to 7.4% during the last 2 years (p less than 0.05). Actuarial survival was 60% at 5 years and 38% at 10 years after reoperation. Among the 53 survivors followed up for an average of 39 months, 47 (88.9%) remained in Class I or II and six were in Class III (11.3%) at last follow-up. A second prosthetic valve replacement (third valve replacement) was required in eight patients, three of whom died at re-replacement. Recent improvements in myocardial protection techniques, in the treatment of prosthetic valve endocarditis, and increased surgical experience have contributed to decrease the risk of reoperation for prosthetic valve replacement. Late results are similar to those of a first valve implantation.

Entities:  

Mesh:

Year:  1984        PMID: 6482488

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Risk factors for short- and long-term survival in patients undergoing re-replacement due to prosthetic valve dysfunction.

Authors:  Bilgehan Savaş Oz; Hikmet Iyem; Hakki Tankut Akay; Cengiz Bolcal; Mehmet Yokusoglu; Erkan Kuralay; Ufuk Demirkilic; Harun Tatar
Journal:  Heart Vessels       Date:  2006-11-27       Impact factor: 2.037

2.  The necessity of reoperation for patients with Bjork-Shiley, St Jude Medical, Hancock and Carpentier-Edwards prostheses.

Authors:  Y Morishita; H Toyohira; T Yuda; Y Umebayashi; H Saigenji; M Hashiguchi; K Uehara; A Taira
Journal:  Jpn J Surg       Date:  1990-07

3.  Triple-valve treatment for prosthetic valve endocarditis occurring 20 years after implantation of a Carpentier-Edwards pericardial bioprosthesis in the aortic valve.

Authors:  Yoichi Hisata; Shiro Hazama; Kenta Izumi; Kiyoyuki Eishi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-12-16

4.  The risks of reoperation for prosthetic valve dysfunction.

Authors:  Y Kawachi; K Matuzaki; R Tominaga; H Yasui; K Tokunaga
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

5.  Reoperation for prosthetic heart valve dysfunction: 19 years' experience.

Authors:  Z Masri; R Girardet; A Attum; R Barbie; I Yared; A Lansing
Journal:  Tex Heart Inst J       Date:  1990

6.  Reoperative Mitral Surgery Versus Transcatheter Mitral Valve Replacement: A Systematic Review.

Authors:  Aditya Sengupta; Farhang Yazdchi; Sophia L Alexis; Edward Percy; Akash Premkumar; Sameer Hirji; Vinayak N Bapat; Deepak L Bhatt; Tsuyoshi Kaneko; Gilbert H L Tang
Journal:  J Am Heart Assoc       Date:  2021-03-09       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.